{
  "content": "ConclusionsIn this study population, there was no difference in the composite of amiodarone and cardiac major adverse events between groups. However, patients receiving episodic treatment had a significantly increased rate of atrial fibrillation recurrence and a significantly higher rate of all-cause mortality and cardiovascular hospitalizations.\nTrial Registrationclinicaltrials.gov Identifier: NCT00392431",
  "source": "https://jamanetwork.com/journals/jama/fullarticle/182743",
  "chunk_id": "c7892a8d-b846-420c-975e-87a4bdf235ca",
  "similarity_score": 0.31997770071029663,
  "query": "long-term outcomes amiodarone beta-blockers atrial fibrillation follow-up recurrence maintenance therapy",
  "rank": 48,
  "title": "Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial Fibrillation: A Randomized Trial",
  "authors": "Sheba Ahmed, MD; Michiel Rienstra, MD, PhD; Harry J. G. M. Crijns, MD, PhD; Thera P. Links, MD, PhD; Ans C. P. Wiesfeld, MD, PhD; Hans L. Hillege, MD, PhD; Hans A. Bosker, MD, PhD; Dirk J. A. Lok, MD; Dirk J. Van Veldhuisen, MD, PhD; Isabelle C. Van Gelder, MD, PhD",
  "year": "2008",
  "journal": "JAMA",
  "reference": "Ahmed, S., Rienstra, M., Crijns, H. J. G. M., Links, T. P., Wiesfeld, A. C. P., Hillege, H. L., Bosker, H. A., Lok, D. J. A., Van Veldhuisen, D. J., & Van Gelder, I. C. (2008). Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: A randomized trial. JAMA, 300(15), 1784â€“1792. https://doi.org/10.1001/jama.300.15.1784",
  "doi": "10.1001/jama.300.15.1784",
  "chunk_index": 20,
  "total_chunks": 106,
  "retrieved_at": "2025-07-24T22:33:54.519443"
}